PRME: Koefisien rega marang pendapatan Prime Medicine Inc
Prime Medicine, Inc. (PRME) focuses on developing methods for the precise correction of genetic defects, funding its research and development through grants. The company's technology stack integrates AI platforms with outsourced production via contract manufacturing organizations. Experienced management ensures the protection of intellectual property. The company's P/S ratio demonstrates capitalization dynamics relative to revenue, where 109.60 reflects the latest metric value for trend analysis.
Rincian analitis perusahaan Prime Medicine Inc (PRME)
- rega saham lan target rega konsensus:
- informasi kapitalisasi pasar:
- rincian nilai buku perusahaan:
- statistik kawajiban utang lan likuiditas:
Rasio Utang marang Ekuitas Prime Medicine, Inc.|PRME - Utang jangka dawa marang modal|Kewajiban jangka cendhak marang modal Prime Medicine|PRME - Gunggung utang perusahaan|Rasio utang marang aset resik Prime Medicine Bio|PRME - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak Prime Medicine|Rasio likuiditas darurat primemedicine.com
- data bathi bisnis lan rasio investasi:
PRME - Bathi resik|Bathi mangsa ngarep Prime Medicine, Inc.|PRME - Koefisien rega marang bathi|Kapitalisasi marang proyeksi bathi Prime Medicine Bio|PRME - Rasio rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi operasional sadurunge panyusutan Prime Medicine|PRME - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajroning taun lumaku Prime Medicine|PRME - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan primemedicine.com|PRME - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep Prime Medicine, Inc.
- rincian pendapatan lan dodolan emiten:
Ringkesan analitik perusahaan:Prime Medicine, PRME
The P/S multiple reflects the market value of Prime Medicine, Inc. (PRME) relative to its actual sales, allowing for an assessment of whether the business is overvalued or undervalued. By analyzing the price-to-sales valuation, an investor can see how the immense vote of confidence in DNA editing technology transforms into capitalization, which is critically important for medical visionaries that have yet to establish a stable cash flow.
Perusahaan pesaing
TEM (Tempus AI, Inc.) - Rasio kapitalisasi pasar marang pendapatan|Qiagen Group - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan IONS|RGEN - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Avidity Biosciences RNA|CRSP: Multiplikator P/S|Rasio kapitalisasi marang pendapatan WGS|RARE (Ultragenyx Pharma) - Multiplikator P/S|Multiplikator P/S Beam Therapeutics Inc.|Rasio rega marang pendapatan Sarepta Therapeutics Inc (SRPT)|Twist Bioscience - Rasio kapitalisasi marang pendapatan|10x Genomics Inc - Kapitalisasi marang pendapatan|NTLA (Intellia Therapeutics, Inc.) - Rasio rega marang dodolan|Stoke Corp - Multiplikator P/S|BLFS (BioLife) - Rasio kapitalisasi marang pendapatan|wavelifesciences.com (WVE) - Rasio rega marang pendapatan|MAZE - Koefisien rega marang pendapatan|SION (Sionna Therapeutics, Inc.) - Multiplikator P/S|Taysha Gene Therapies, Inc. - Rasio rega marang dodolan|Multiplikator P/S QURE|MGTX: Rasio rega marang dodolan|Rasio rega marang pendapatan REGENXBIO RGNX|SLDB: Rasio kapitalisasi marang pendapatan|OCGN: Kapitalisasi marang pendapatan|PACB - Multiplikator P/S|BNTC (Benitec Corp) - Kapitalisasi marang pendapatan|Multiplikator rega marang pendapatan Design Corp DSGN|Rasio rega marang pendapatan Rocket Pharmaceuticals|Multiplikator P/S 4D Molecular Therapeutics, Inc.|Rasio rega marang pendapatan Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S EDIT (Editas Medicine, Inc.)|Multiplikator P/S Silence Therapeutics Corp SLN|PRQR - Rasio rega marang pendapatan|Koefisien rega marang pendapatan Codexis Inc CDXS|SGMO: Multiplikator P/S|Rasio kapitalisasi marang pendapatan NAUT|Rasio rega marang pendapatan metagenomi.co|Multiplikator P/S Precision BioSciences Inc.|Multiplikator P/S GBIO|Boundless Bio, Inc. - Rasio kapitalisasi marang pendapatan|Multiplikator P/S XCUR (Exicure, Inc.)|Koefisien rega marang pendapatan Imunon, Inc. (IMNN)|PHIO - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan MBIO (mustangbio.com)|RNAZ: Multiplikator P/S|Rasio kapitalisasi marang pendapatan BNGO|APDN (Applied DNA Corp) - Multiplikator P/S|BLUE: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan ImmunoPrecise (IPA)|OMGA - Rega marang dodolan|Rasio rega marang pendapatan Singular Genomics OMIC|Rasio kapitalisasi pasar marang pendapatan RGLS|Syros Pharmaceuticals, Inc. - Multiplikator P/S|Koefisien rega marang pendapatan Telesis Bio Inc. TBIO|TRACON Pharmaceuticals, Inc. (TCON) - Rasio rega marang pendapatan|Unity Biotechnology, Inc - Rasio kapitalisasi pasar marang pendapatan
